These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 31549317)

  • 21. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage.
    Zhu GA; Sundram U; Chang AL
    JAMA Dermatol; 2014 Sep; 150(9):970-3. PubMed ID: 24740281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vismodegib in the treatment of advanced BCC.
    O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
    Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacologic treatment options for advanced epithelial skin cancer.
    Soura E; Chasapi V; Stratigos AJ
    Expert Opin Pharmacother; 2015; 16(10):1479-93. PubMed ID: 26027692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Libtayo
    Gupta AK; Mann A; Vincent K; Abramovits W
    Skinmed; 2024; 22(2):138-143. PubMed ID: 39090000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities.
    Sol S; Boncimino F; Todorova K; Waszyn SE; Mandinova A
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
    Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
    Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.
    Saintes C; Saint-Jean M; Brocard A; Peuvrel L; Renaut JJ; Khammari A; Quéreux G; Dréno B
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):1006-9. PubMed ID: 24980899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolving Role of Systemic Therapies in Non-melanoma Skin Cancer.
    Conforti C; Corneli P; Harwood C; Zalaudek I
    Clin Oncol (R Coll Radiol); 2019 Nov; 31(11):759-768. PubMed ID: 31522944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.
    Mohan SV; Chang J; Li S; Henry AS; Wood DJ; Chang AL
    JAMA Dermatol; 2016 May; 152(5):527-32. PubMed ID: 26914338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.
    Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST
    J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Divergent response to PD-L1 inhibition in advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma.
    Salzmann M; Löser C; Hassel JC
    J Dtsch Dermatol Ges; 2023 Jul; 21(7):803-805. PubMed ID: 37066606
    [No Abstract]   [Full Text] [Related]  

  • 33. Update on the Use and Treatment of Targeted Molecular Inhibitors for Locally Advanced and Metastatic Non-Melanoma Skin Cancers.
    Odueyungbo M; Ratner D
    Dermatol Surg; 2016 Jan; 42 Suppl 1():S49-56. PubMed ID: 26730974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Merkel cell carcinoma in a stem cell transplant patient.
    Miller J; Huhn K; Goldman G; Dzubow L
    Dermatol Surg; 1998 Aug; 24(8):913-4. PubMed ID: 9723061
    [No Abstract]   [Full Text] [Related]  

  • 35. Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers.
    Ravipati A; Pradeep T; Nouri K
    J Drugs Dermatol; 2024 May; 23(5):301-305. PubMed ID: 38709693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surgery in the Era of Immunotherapy for Advanced Head and Neck Non-melanoma Skin Cancer.
    Lin A; Schmalbach CE
    Curr Oncol Rep; 2023 Jul; 25(7):735-742. PubMed ID: 37010785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cytokines: current status and prospects in the treatment of skin tumors].
    Nashan D; Luger TA
    Hautarzt; 2001 Aug; 52(8):691-6. PubMed ID: 11544938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma.
    Dubey AK; Dubey S; Handu SS; Qazi MA
    J Postgrad Med; 2013; 59(1):48-50. PubMed ID: 23525058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma.
    Bradford D; Demko S; Jin S; Mishra-Kalyani P; Beckles AR; Goldberg KB; Lemery S; Ward A; Keegan P; Pazdur R
    Oncologist; 2020 Jul; 25(7):e1077-e1082. PubMed ID: 32272501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Nonmelanoma Skin Cancers, Melanoma, and Merkel Cell Carcinoma with Dermatologic Medications: A Case-Control Pharmacovigilance Study of the FDA Adverse Events Reporting System.
    Jedlowski PM
    Dermatology; 2023; 239(5):694-699. PubMed ID: 37054693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.